Top

BMC Pulmonary Medicine

Published in:

Open Access 01-12-2020 | Isoniazid | Case report

Hepatitis in children with tuberculosis: a case report and review of the literature

Authors: Maria Sanchez-Codez, W. Garret Hunt, Joshua Watson, Asuncion Mejias

Published in: BMC Pulmonary Medicine | Issue 1/2020

Abstract

Background

Hepatitis in young children with tuberculosis (TB) outside miliary TB is not well described and represents a challenge because of the hepatotoxicity associated with first-line anti-TB treatment.

Case presentation

We report an antibiotic naïve 13-month-old male from Nepal with pulmonary TB and hepatitis, who improved after TB treatment. We also performed a literature review for TB-associated hepatitis in children.

Conclusions

Liver function tests should be considered, when feasible, in infants and young children with pulmonary TB. Testing could help to identify and manage patients with TB-associated hepatic abnormalities, and also to establish a baseline for detection and management of liver injury associated with anti-TB therapy.

Available only for authorised users

Global Tuberculosis Report. Geneva: World Health Organization (WHO); 2019. License: CC BY-NC-SA 3.0 IGO. [Online]: https://www.who.int/tb/publications/global_report/en/2018. Accessed Feb 2020.

Evans RP, Mourad MM, Dvorkin L, Bramhall SR. Hepatic and intra-abdominal tuberculosis: 2016 update. Curr Infect Dis Rep. 2016;18(12):45. https://doi.org/10.1007/s11908-016-0546-5.CrossRefPubMed

Nahid P, Dorman SE, Alipanah N, Barry PM, Brozek JL, Cattamanchi A, et al. Executive summary: official American thoracic society/centers for disease control and prevention/infectious diseases society of America clinical practice guidelines: treatment of drug-susceptible tuberculosis. Clin Infect Dis. 2016;63(7):853–67. https://doi.org/10.1093/cid/ciw566.CrossRefPubMedPubMedCentral

Shastri M, Kausadikar S, Jariwala J, Dave D, Patell R. Isolated hepatic tuberculosis: an uncommon presentation of a common culprit. Australas Med J. 2014;7(6):247–50. https://doi.org/10.4066/AMJ.2014.2076.CrossRefPubMedPubMedCentral

American Thoracic S, Cdc, Infectious Diseases Society of A. Treatment of tuberculosis. MMWR Recomm Rep. 2003;52(RR-11):1–77.

Nandan D, Bhatt GC, Dewan V, Yadav TP, Singh S. Isolated tuberculous liver abscess in a 3-year-old immunocompetent child. Paediatr Int Child Health. 2013;33(3):187–9. https://doi.org/10.1179/2046905512Y.0000000033.CrossRefPubMed

Mojtahedzadeh M, Otoukesh S, Shahsafi MR, Tahbaz MO, Rahvari SK, Poorabdollah M, et al. Case report: portal hypertension secondary to isolated liver tuberculosis. Am J Trop Med Hyg. 2012;87(1):162–4. https://doi.org/10.4269/ajtmh.2012.11-0643.CrossRefPubMedPubMedCentral

Al Umairi R, Al Abri A, Kamona A. Tuberculosis (TB) of the porta hepatis presenting with obstructive jaundice mimicking a malignant biliary tumor: a case report and review of the literature. Case Rep Radiol. 2018;2018:5318197. https://doi.org/10.1155/2018/5318197.CrossRefPubMed

Kandasamy S, Govindarajalou R, Chakkalakkoombil SV, Penumadu P. Isolated hepatobiliary tuberculosis: a diagnostic challenge. BMJ Case Rep. 2018;2018. https://doi.org/10.1136/bcr-2017-223912.

10.

Saukkonen JJ, Cohn DL, Jasmer RM, Schenker S, Jereb JA, Nolan CM, et al. An official ATS statement: hepatotoxicity of antituberculosis therapy. Am J Respir Crit Care Med. 2006;174(8):935–52. https://doi.org/10.1164/rccm.200510-1666ST.CrossRefPubMed

11.

Ohkawa K, Hashiguchi M, Ohno K, Kiuchi C, Takahashi S, Kondo S, et al. Risk factors for antituberculous chemotherapy-induced hepatotoxicity in Japanese pediatric patients. Clin Pharmacol Ther. 2002;72(2):220–6. https://doi.org/10.1067/mcp.2002.126175.CrossRefPubMed

12.

Tsagaropoulou-Stinga H, Mataki-Emmanouilidou T, Karida-Kavalioti S, Manios S. Hepatotoxic reactions in children with severe tuberculosis treated with isoniazid-rifampin. Pediatr Infect Dis. 1985;4(3):270–3. https://doi.org/10.1097/00006454-198505000-00013.CrossRefPubMed

13.

Donald PR. Antituberculosis drug-induced hepatotoxicity in children. Pediatr Rep. 2011;3(2):e16. https://doi.org/10.4081/pr.2011.e16.CrossRefPubMedPubMedCentral

Title: Hepatitis in children with tuberculosis: a case report and review of the literature
Authors: Maria Sanchez-Codez
W. Garret Hunt
Joshua Watson
Asuncion Mejias
Publication date: 01-12-2020
Publisher: BioMed Central
Keywords: Isoniazid
Tuberculosis
Mycobacterium Tuberculosis
Levofloxacin
Liver Function Test
Amikacin
Tuberculosis
Ethambutol
Pyrazinamide
Linezolid
Hepatitis
Published in: BMC Pulmonary Medicine / Issue 1/2020
Electronic ISSN: 1471-2466
DOI: https://doi.org/10.1186/s12890-020-01215-6

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Hepatitis in children with tuberculosis: a case report and review of the literature

Abstract

Background

Case presentation

Conclusions

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Background

Case presentation

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2020

LncRNA SNHG10 is downregulated in non-small cell lung cancer and predicts poor survival

LncRNA TUG1 alleviates sepsis-induced acute lung injury by targeting miR-34b-5p/GAB1

Inhibition of connexin 43 attenuates oxidative stress and apoptosis in human umbilical vein endothelial cells

Multiple intraventricular metastases from lung adenocarcinoma with EGFR G719X mutation: a case report

Recovery from hypoxemia and Hypercapnia following noninvasive pressure support ventilation in a patient with statin-associated necrotizing myopathy: a case report

IL-32 induces epithelial-mesenchymal transition by triggering endoplasmic reticulum stress in A549 cells

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page